Rite Aid Fights $200 Million Bill After MedImpact Buys Elixir

<-rte-company state="{"_id":"00000190-3c31-d497-a7fb-fc3d10470000","_type":"00000160-4b23-d8bd-adfd-4b3348fd0000"}">Rite Aid Corp. and <-bsp-bb-link state="{"bbHref":"bbg://securities/0193751D%20US%20Equity","_id":"00000190-3c31-d497-a7fb-fc3d10470002","_type":"0000016b-944a-dc2b-ab6b-d57ba1cc0000"}">MedImpact Healthcare Systems Inc. are fighting over which company is responsible for more than $200 million in extra costs connected with an acquisition, a fresh hurdle for the pharmacy company as it attempts to forge a path out of bankruptcy.

The companies completed a trial Friday in New Jersey bankruptcy court over whether MedImpact is on the hook for paying the additional liabilities on top of <-bsp-bb-link state="{"bbDocId":"SEKLS2DWLU68","_id":"00000190-3c31-d497-a7fb-fc3d10470003","_type":"0000016b-944a-dc2b-ab6b-d57ba1cc0000"}">$575 million it paid to acquire pharmacy benefit manager Elixir from Rite Aid. Some of the expenses include millions of dollars in unpaid reimbursements owed to CVS Health Corp., Walgreens ...